NCT04603183
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with known active progressive brain metastases – see trial for details; Patients with leptomeningeal disease; Patients with prior systemic therapy for metastatic disease
https://ClinicalTrials.gov/show/NCT04603183